Diagnosis of nonalcoholic fatty liver disease: The importance of pathology

Aiping TIAN; Yongfeng YANG

doi:10.3969/j.issn.1001-5256.2023.03.002

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 491-497

PDF( 3621 KB)

Diagnosis of nonalcoholic fatty liver disease: The importance of pathology

DOI: 10.3969/j.issn.1001-5256.2023.03.002

Aiping TIAN¹,
Yongfeng YANG^{2
,
,
,}

1.
Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China
2.
Department of Hepatology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210003, China

Research funding:

Gansu Province Academic Innovative Promotion (2020B-016);

The Inner Project of the 1st hospital of Lanzhou University (ldyyyn2018-62)

More Information

Corresponding author: YANG Yongfeng, yyf1997@163.com (ORCID: 0000-0002-3214-0038)
Received Date: 2022-01-15
Accepted Date: 2022-02-20
Published Date: 2023-03-20

Abstract

Abstract

Histopathological evaluation based on liver biopsy is required to make a confirmed diagnosis of nonalcoholic fatty liver disease, differentiate nonalcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH), and perform the grading and scoring of disease severity, while hematological and radiological examinations are often used in clinical practice. Although there have been a large number of studies on noninvasive models for fibrosis assessment and disease diagnosis in nonalcoholic fatty liver disease, the sensitivity and specificity of such models need to be further improved. This article reviews the main pathological features of NAFL and NASH, fibrosis and grading/staging/scoring systems, and the pathological diagnosis of NASH liver cirrhosis, in order to improve the awareness of the histological diagnosis of such disease among clinicians
- Non-alcoholic Fatty Liver Disease,
- Pathology,
- Diagnosis, Differential

FullText(HTML)

References(25)

References

[1]	LOOMBA R, ADAMS LA. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH[J]. Hepatology, 2019, 70(6): 1885-1888. DOI: 10.1002/hep.30946.
[2]	SAXENA R. Practical hepatic pathology, a diagnostic approach[M]. 2nd edition. Philadelphia, PA: Elsevier, 2017.
[3]	BRIL F, BARB D, PORTILLO-SANCHEZ P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease[J]. Hepatology, 2017, 65(4): 1132-1144. DOI: 10.1002/hep.28985.
[4]	POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22(1): 63. DOI: 10.1186/s12902-022-00980-1.
[5]	BRUNT EM, KLEINER DE, CARPENTER DH, et al. NAFLD: Reporting histologic findings in clinical practice[J]. Hepatology, 2021, 73(5): 2028-2038. DOI: 10.1002/hep.31599.
[6]	BRUNT EM. Pathology of fatty liver disease[J]. Mod Pathol, 2007, 20 (Suppl 1): S40-S48.
[7]	FELDSTEIN AE, WIECKOWSKA A, LOPEZ AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study[J]. Hepatology, 2009, 50(4): 1072-1078. DOI: 10.1002/hep.23050.
[8]	DUAN Y, PAN X, LUO J, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
[9]	SANYAL AJ, HARRISON SA, RATZIU V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials[J]. Hepatology, 2019, 70(6): 1913-1927. DOI: 10.1002/hep.30664.
[10]	BRUNT EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond[J]. Hepatology, 2000, 31(1): 241-246. DOI: 10.1002/hep.510310136.
[11]	LUO J, LIU LW, LIU JM, et al. Comparative study of clinicopathological features, and risk factors of advanced fibrosis between genders with non-alcoholic fatty liver disease[J]. Chin J Hepatol, 2021, 29(4): 356-361. DOI: 10.3760/cma.j.cn501113-20200203-00027. 罗娟, 刘立伟, 刘纪民, 等. 非酒精性脂肪性肝病临床和病理特点及进展期纤维化危险因素性别差异的对比研究[J]. 中华肝脏病杂志, 2021, 29(4): 356-361. DOI: 10.3760/cma.j.cn501113-20200203-00027.
[12]	ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149(2): 389-397. e10. DOI: 10.1053/j.gastro.2015.04.043.
[13]	TIAN AP, YANG YF. A comparative analysis of pathological grading and staging systems for chronic hepatitis[J]. J Clin Hepatol, 2018, 34(11): 2271-2277. DOI: 10.3969/j.issn.1001-5256.2018.11.002. 田爱平, 杨永峰. 慢性肝炎病理学分级分期评分系统比较[J]. 临床肝胆病杂志, 2018, 34(11): 2271-2277. DOI: 10.3969/j.issn.1001-5256.2018.11.002.
[14]	KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
[15]	BEDOSSA P, POITOU C, VEYRIE N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients[J]. Hepatology, 2012, 56(5): 1751-1759. DOI: 10.1002/hep.25889.
[16]	ALKHOURI N, de VITO R, ALISI A, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease[J]. J Hepatol, 2012, 57(6): 1312-1318. DOI: 10.1016/j.jhep.2012.07.027.
[17]	CLEVELAND E, BANDY A, VANWAGNER LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Clin Liver Dis (Hoboken), 2018, 11(4): 98-104. DOI: 10.1002/cld.716.
[18]	LONGERICH T, SCHIRMACHER P. Determining the reliability of liver biopsies in NASH clinical studies[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(11): 653-654. DOI: 10.1038/s41575-020-00363-8.
[19]	CASTERA L, FRIEDRICH-RUST M, LOOMBA R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156(5): 1264-1281. e4. DOI: 10.1053/j.gastro.2018.12.036.
[20]	KWOK R, TSE YK, WONG GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments[J]. Aliment Pharmacol Ther, 2014, 39(3): 254-269. DOI: 10.1111/apt.12569.
[21]	MIDDLETON MS, HEBA ER, HOOKER CA, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis[J]. Gastroenterology, 2017, 153(3): 753-761. DOI: 10.1053/j.gastro.2017.06.005.
[22]	TAOULI B, SERFATY L. Magnetic resonance imaging/elastography is superior to transient elastography for detection of liver fibrosis and fat in nonalcoholic fatty liver disease[J]. Gastroenterology, 2016, 150(3): 553-556. DOI: 10.1053/j.gastro.2016.01.017.
[23]	WILDMAN-TOBRINER B, MIDDLETON MM, MOYLAN CA, et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155(5): 1428-1435. e2. DOI: 10.1053/j.gastro.2018.07.018.
[24]	NOUREDDIN M, TRUONG E, GORNBEIN JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76(4): 781-787. DOI: 10.1016/j.jhep.2021.11.012.
[25]	RINELLA ME, TACKE F, SANYAL AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD[J]. J Hepatol, 2019, 71(4): 823-833. DOI: 10.1016/j.jhep.2019.04.019.

Relative Articles

[1]	Qiupeng WANG, Meifu GAN. Pathological diagnosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1088-1092. doi: 10.12449/JCH240604
[2]	Wenjun YANG. Pathological diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1082-1087. doi: 10.12449/JCH240603
[3]	Jiping ZHANG. Pathological diagnosis of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1093-1099. doi: 10.12449/JCH240605
[4]	Bin WANG. Pathological diagnosis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1076-1081. doi: 10.12449/JCH240602
[5]	Ke SUN. Pathological diagnosis of autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1100-1106. doi: 10.12449/JCH240606
[6]	Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003
[7]	Mengmeng ZHANG, Yao MENG, Xinyan ZHAO. Differential pathological diagnosis of liver tissue with normal appearance[J]. Journal of Clinical Hepatology, 2023, 39(3): 517-522. doi: 10.3969/j.issn.1001-5256.2023.03.006
[8]	Xinhang SONG, Juanhan YU, Zhaoping CHENG, Chen SHAO, Baocheng DENG. Pathological staging systems of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(3): 653-655. doi: 10.3969/j.issn.1001-5256.2022.03.033
[9]	Si XIE, Ming YANG, Yuan HUANG, Lai WEI. Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report[J]. Journal of Clinical Hepatology, 2021, 37(2): 400-402. doi: 10.3969/j.issn.1001-5256.2021.02.030
[10]	Zhu HongMei, Wang QinYing. Advances in the diagnosis and treatment of nonalcoholic fatty liver disease-related liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 178-181. doi: 10.3969/j.issn.1001-5256.2020.01.042
[11]	Gong Hang, Li LiangPing. Noninvasive diagnosis of progressive nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 406-410. doi: 10.3969/j.issn.1001-5256.2019.02.038
[12]	Feng Gong, Han HaiJing, Qi Xue, Mi Man, Tian QiuMei, Niu ChunYan. Establishment of a noninvasive diagnosis equation for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1264-1267. doi: 10.3969/j.issn.1001-5256.2018.06.026
[13]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[14]	Tian AiPing, Yang YongFeng. A comparative analysis of pathological grading and staging systems for chronic hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2271-2277. doi: 10.3969/j.issn.1001-5256.2018.11.002
[15]	Wu DongBo, Chen EnQiang, Bai Lang, Tang Hong. Liver biopsy and related techniques in pathological diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2295-2299. doi: 10.3969/j.issn.1001-5256.2018.11.006
[16]	Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
[17]	Luo WenPing, Ma Hong, Zhao XinYan. Pathological features of hepatic vascular diseases and key points in differential diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2289-2294. doi: 10.3969/j.issn.1001-5256.2018.11.005
[18]	Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Pathology, Chinese Anti-Cancer Association, Digestive Disease Group, Chinese Society of Pathology, Chinese Medical Association, epatic Surgery Group, Chinese Society of Surgery, Chinese Medical Association, Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association, Chinese Pathological Group of Hepatobiliary Tumor and Liver Transplantation. Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China( 2015 update)[J]. Journal of Clinical Hepatology, 2015, 31(6): 833-839. doi: 10.3969/j.issn.1001-5256.2015.06.004
[19]	Lang ZhenWei. Pathological advances in autoimmune liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 326-331.

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	莫双阳，伍文红，韦海小，覃海燕，李俩. 综合生物信息学与机器学习筛选非酒精性脂肪性肝炎的趋化因子相关核心基因. 河北医科大学学报. 2024(02): 165-171 .
2.	郭紫薇，武庆娟，叶永安，陈兰羽，吕文良. 孟德尔随机化分析方法在非酒精性脂肪性肝病病因探索中的应用. 临床肝胆病杂志. 2024(03): 589-593 . 本站查看
3.	刘嘉玲，孙劲晖. 非酒精性脂肪性肝病更名：从代谢功能障碍相关脂肪肝异质性到“同病异治”. 中国中西医结合消化杂志. 2024(05): 450-454 .
4.	周晓玲，刘琳，吴腾，沈新辉，孙东琪，磨奕玲. 基于“土壅木郁”探讨加味理中汤治疗非酒精性脂肪性肝炎的理论基础. 中西医结合肝病杂志. 2024(05): 457-460 .
5.	胡涛，王冰钰，苏薇薇，彭维，黎建华，李常青，周毅业，郭洁文. 基于UPLC-Zone TOF-MS/MS联合网络药理学探讨脉复生防治NAFLD作用. 中山大学学报(自然科学版中英文). 2024(05): 73-82 .
6.	冯巩，孔荣耀，王嘉学，吴天悦，武晓慧，王菊宁，严琴琴，弥曼. 纤维化非酒精性脂肪性肝炎无创诊断的研究进展. 临床肝胆病杂志. 2024(11): 2293-2299 . 本站查看
7.	饶静，张汝，黄旭东，蔡弟，盛琛，杨传留，陈敬. 维生素D联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病临床效果及其对血清纤溶酶原激活剂抑制物、组织蛋白酶D影响. 临床军医杂志. 2023(06): 582-586 .
8.	章秀丽，李庆群，张绍荣，张楚新. Leu72Met rs696217基因多态性与非酒精性脂肪性肝病遗传易感性的关系. 国际消化病杂志. 2023(03): 159-164 .
9.	李超波，杨丽媛，王春梅，宋井一，郝艳艳，曹立瀛，马向明. 饮食诱导的小鼠非酒精性脂肪性肝病进展中糖代谢酶的变化. 中国病理生理杂志. 2023(11): 2067-2074 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (1519) PDF downloads(492)

Diagnosis of nonalcoholic fatty liver disease: The importance of pathology

DOI: 10.3969/j.issn.1001-5256.2023.03.002